Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07332143 · ClinicalTrials.gov registry record · Phase 2
Psilocybin-Assisted Therapy
A Phase 2 study, sponsored by Emory University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT07332143 is a Phase 2 study that has not yet begun recruiting, run by Emory University. The registered enrollment target is 150 participants.
The verdict
NCT07332143, a Phase 2 study, has not yet begun recruiting, sponsored by Emory University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin and psilocybin-assisted psychotherapy.
Interventions
- BEHAVIORAL Supportive Therapy
- BEHAVIORAL Prolonged Exposure Therapy
- DRUG psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07332143
The ClinicalTrials.gov registry entry for NCT07332143 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Supportive Therapy is the first listed.
NCT07332143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07332143 about?
NCT07332143 is a clinical study titled "Psilocybin-Assisted Therapy". This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin an...
What is the current status of trial NCT07332143?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-06. Estimated completion is 2027-03.
What interventions are being tested in trial NCT07332143?
The interventions under investigation include: Supportive Therapy (BEHAVIORAL), Prolonged Exposure Therapy (BEHAVIORAL), psilocybin (DRUG).
Who is sponsoring clinical trial NCT07332143?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.